{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:50:04Z","timestamp":1783648204869,"version":"3.55.0"},"reference-count":32,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010443","name":"RACP Foundation","doi-asserted-by":"publisher","award":["2022RES00038"],"award-info":[{"award-number":["2022RES00038"]}],"id":[{"id":"10.13039\/501100010443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010443","name":"RACP Foundation","doi-asserted-by":"publisher","award":["IPAP2021\/0339"],"award-info":[{"award-number":["IPAP2021\/0339"]}],"id":[{"id":"10.13039\/501100010443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Carriers of germline pathogenic variants (PVs) in succinate dehydrogenase type B (SDHB) are at increased risk of developing pheochromocytomas and paragangliomas (PPGLs). Understanding their outcomes can guide recommendations for risk assessment and early detection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We performed a systematic review and meta-analysis of the following outcomes in SDHB PV carriers: age-specific risk of developing tumors, metastatic progression, second primary tumor development, and mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed, MEDLINE, and EMBASE were searched. Sixteen studies met the inclusion criteria and were sorted into 4 outcome categories: age-specific penetrance, metastatic disease, risk of second tumor, and mortality. We assessed heterogeneity and performed a meta-analysis across studies using a random-effects model with the DerSimonian and Laird method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Penetrance of PPGLs for nonproband\/nonindex SDHB PV carriers by age 20 was 4% (95% CI, 3%-6%), 11% (95% CI, 8%-15%) by age 40, 24% (95% CI, 19%-31%) by age 60%, and 35% (95% CI, 25%-47%) by age 80. The overall risk of metastatic disease for nonproband\/nonindex carriers with PPGLs was 9% (95%, CI 5%-16%) per lifetime. In all affected cases (combining both proband\/index and nonproband\/nonindex carriers with tumors), the risk of a second tumor was 24% (95% CI, 18%-31%) and all-cause 5-year mortality was 18% (95% CI, 6%-40%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Penetrance for PPGLs in SDHB PV carriers increases linearly with age. Affected carriers are at risk of developing and dying of metastatic disease, or of developing second tumors. Lifelong surveillance is appropriate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae233","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T03:03:20Z","timestamp":1712891000000},"page":"2400-2410","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of <i>SDHB<\/i> Pathogenic Variant Carriers"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4084-9239","authenticated-orcid":false,"given":"Dahlia F","family":"Davidoff","sequence":"first","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia"},{"name":"Faculty of Medicine and Health, University of Sydney , Northern Sydney (Arabanoo) Precinct, St Leonards, NSW 2065 , Australia"},{"name":"Department of Endocrinology, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"De Abreu Lourenco","sequence":"additional","affiliation":[{"name":"Centre for Health Economics Research and Evaluation, University of Technology Sydney , Haymarket, Sydney 2007 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa H M","family":"Tsang","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia"},{"name":"Faculty of Medicine and Health, University of Sydney , Northern Sydney (Arabanoo) Precinct, St Leonards, NSW 2065 , Australia"},{"name":"Department of Endocrinology, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana E","family":"Benn","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia"},{"name":"Faculty of Medicine and Health, University of Sydney , Northern Sydney (Arabanoo) Precinct, St Leonards, NSW 2065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-0368","authenticated-orcid":false,"given":"Roderick J","family":"Clifton-Bligh","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia"},{"name":"Faculty of Medicine and Health, University of Sydney , Northern Sydney (Arabanoo) Precinct, St Leonards, NSW 2065 , Australia"},{"name":"Department of Endocrinology, Royal North Shore Hospital , St Leonards, NSW 2065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"6","key":"2024081223530774800_dgae233-B1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"2024081223530774800_dgae233-B2","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2017","edition":"4th ed"},{"issue":"7","key":"2024081223530774800_dgae233-B3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2024081223530774800_dgae233-B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jmedgenet-2020-107656","article-title":"SDHB variant type impacts phenotype and malignancy in pheochromocytoma\u2013paraganglioma","volume":"60","author":"Bayley","year":"2023","journal-title":"J Med Genet"},{"issue":"5","key":"2024081223530774800_dgae233-B5","doi-asserted-by":"crossref","first-page":"e1907","DOI":"10.1210\/clinem\/dgac019","article-title":"Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multicenter study","volume":"107","author":"Davidoff","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"issue":"10","key":"2024081223530774800_dgae233-B6","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/cancers13102389","article-title":"Mutation profile of aggressive pheochromocytoma and paraganglioma with comparison of tcga data","volume":"13","author":"Choi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2024081223530774800_dgae233-B7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2024081223530774800_dgae233-B8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2024081223530774800_dgae233-B9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmedgenet-2019-106324","article-title":"Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis","volume":"57","author":"Lee","year":"2020","journal-title":"J Med Genet"},{"issue":"12","key":"2024081223530774800_dgae233-B10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/jmedgenet-2012-101192","article-title":"Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis","volume":"49","author":"van Hulsteijn","year":"2012","journal-title":"J Med Genet"},{"issue":"6","key":"2024081223530774800_dgae233-B11","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metabol"},{"issue":"10","key":"2024081223530774800_dgae233-B12","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"2024081223530774800_dgae233-B13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/cen.13246","article-title":"Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers","volume":"86","author":"Tufton","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024081223530774800_dgae233-B14","doi-asserted-by":"crossref","unstructured":"Davidoff DF, De Abreu Lourenco R, Tsang VH, Benn DE, Clifton-Bligh RJ. Data from: Supplemental Material Outcomes of SDHB pathogenic variant carriers a systematic review and meta-analysis [Data set]. Zenodo; 2023. https:\/\/doi.org\/10.5281\/zenodo.8423607.","DOI":"10.1210\/clinem\/dgae233"},{"key":"2024081223530774800_dgae233-B15","volume-title":"Epidemiology of Study Design","author":"Munnangi","year":"2023"},{"issue":"6","key":"2024081223530774800_dgae233-B16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet"},{"key":"2024081223530774800_dgae233-B17","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"2024081223530774800_dgae233-B18","doi-asserted-by":"crossref","DOI":"10.1002\/0470870168","volume-title":"Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments","author":"Rothstein","year":"2005"},{"issue":"1","key":"2024081223530774800_dgae233-B19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/ERC-13-0415","article-title":"Long-term prognosis of patients with pediatric pheochromocytoma","volume":"21","author":"Bausch","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2024081223530774800_dgae233-B20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-16-0595","article-title":"Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase mutations","volume":"175","author":"Daniel","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024081223530774800_dgae233-B21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10689-016-9923-3","article-title":"Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers","volume":"16","author":"Eijkelenkamp","year":"2017","journal-title":"Fam Cancer"},{"issue":"6","key":"2024081223530774800_dgae233-B22","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/cen.12074","article-title":"Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma","volume":"78","author":"Jafri","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2024081223530774800_dgae233-B23","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-017-2397-3","article-title":"SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations","volume":"143","author":"Jochmanova","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2024081223530774800_dgae233-B24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00432-020-03138-5","article-title":"Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents","volume":"146","author":"Jochmanova","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"31","key":"2024081223530774800_dgae233-B25","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024081223530774800_dgae233-B26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/EJE-17-0074","article-title":"The phenotype of SDHB germline mutation carriers: a nationwide study","volume":"177","author":"Niemeijer","year":"2017","journal-title":"European journal of endocrinology"},{"issue":"1","key":"2024081223530774800_dgae233-B27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/1471-2407-14-523","article-title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study","volume":"14","author":"Schovanek","year":"2014","journal-title":"BMC cancer"},{"issue":"4","key":"2024081223530774800_dgae233-B28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2265.2008.03274.x","article-title":"Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers","volume":"69","author":"Srirangalingam","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2024081223530774800_dgae233-B29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"issue":"2","key":"2024081223530774800_dgae233-B30","doi-asserted-by":"crossref","first-page":"e210602","DOI":"10.1530\/EC-21-0602","article-title":"Tumour detection and outcomes of surveillance screening in SDHB and SDHD pathogenic variant carriers","volume":"11","author":"White","year":"2022","journal-title":"Endocr Connect"},{"issue":"6","key":"2024081223530774800_dgae233-B31","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-PronO study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"2024081223530774800_dgae233-B32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae233\/57678464\/dgae233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2400\/58769941\/dgae233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2400\/58769941\/dgae233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T01:11:00Z","timestamp":1723511460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/9\/2400\/7644369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae233","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,12]]}}}